Meanwhile, Neurocrine Biosciences (NBIX), another commercial-stage biotech with a focus on neurological disorders, similar to Biohaven (BHVN), has recorded the biggest intraday gain following the news of the deal. NBIX has been around forever.
IT'S GOING TO BE HARD LEAVING A BARE ESSENTIAL THREAD IN THIS SORT OF MARKET. I think we have to keep this going until the market fixes itself and that may be quite some while. Until then RADIO SAVANT will be an added bonus.... THE BEST $4 STOCK IN THE WORLD---- Clean Energy Fuels upgraded at Raymond James after decade on the sidelines May 10, 2022 10:51 AM ETClean Energy Fuels Corp. (CLNE) Clean Energy Fuels (NASDAQ:CLNE)+3.2%in Tuesday's trading, bouncing off 17-month lows, as Raymond Jamesu pgrades shares to Outperform from Market Perform with a $6 price target, turning positive on the stock for thefirst time since 2012. "We still have some concerns - this is an incentive sensitive business, and CNG will need to contend with electric buses and trucks - but the risk/reward is finally at a point where we can rationally recommend the shares," Ray Jay's Pavel Molchanov writes. The likely reinstatement of the federal Alternative Fuel Tax Credit represents an important catalyst coming up, according to Molchanov, whose model points to near-record EBITDA in 2023 even without the AFTC, approaching the pre-COVID peak of $86M in 2019. Clean Energy (CLNE) is diversifying from its historical status as purely a fuel distributor to starting in-house production of renewable natural gas in 2023, but "the growth story must be balanced against the fact that this commodity business is highly sensitive to both federal and state policy incentives, including a high degree of reliance on California credits," Molchanov writes.
Reata Pharma surges as Goldman sets a Street high target May 10, 2022 11:57 AM ET Reata Pharmaceuticals, Inc. (RETA) Clinical-stage biopharma company, Reata Pharmaceuticals (NASDAQ:RETA) ended a three-day losing streak on Tuesday after Goldman Sachs raised its price target to a Street high of $93 following the Texas-based firm’s 1Q 2022 results. Despite themixed quarterly performance, the analysts led by Madhu Kumar focused on the company’s regulatory path towards approval of its lead asset, Omaveloxolone in Friedreich’s Ataxia. Reata (RETA) has completed the rolling submission of the U.S. marketing application for the candidate. Goldman expects the FDA to provide feedback and accept the filing by May 30 with a potential AdCom meeting and a PDUFA date. Following the price revision driven by a model update, the firm maintains the Buy rating on the stock. With a Buy rating, Reata (RETA) currently has an average price target of $59.67 on Wall Street.
The terrain in Ukraine is soggier than Spain. (5 times fast) These tanks they should be driving abreast in a long straight line then as one gets hit another can return fire. This driving tanks down paved roads because the ground is boggy! Is Nutso! <<<<<<<<<<<<<<<<<<<<< Sit back friends and enjoy this...
We all have important times in our lives. Truly important times. When life is so damn good. You remember the smells, the sites, the parties, the fashion... THIS IS RADIO SAVANT
Greetings Ted- Yes Tech is a minefield. Oh wait here comes my tech play... HOLD YOUR HATS!!! This is the same sector that has halved many a poor soul... ---------->Flywire sees Q2 revenue $50M-$53M, consensus $47.26M 16:43 FLYW -------------->Flywire raises FY22 revenue view $269M-$279M from $266M-$276M 16:43 FLYW FY22 revenue consensus $253.72M ---------->> Flywire reports Q1 EPS (10c), consensus (3c) 16:41 FLYW Reports Q1 revenue…
Just got back from a seedy bar and biotech is being bantered about-- I know one that makes money is small and already being talked about as a possible M&A WATCH->Surface Oncology, Inc. (SURF)- Very good vol day today NasdaqGM - NasdaqGM Real Time Price. Currency in USD 2.2100+0.2100 (+10.50%)<----------- At close: 04:00PM EDT
I missed it at $29 when you first recommended it. Is it a good buy at $19 now? 33% haircut. Not exactly a -50% upstart trade, but at least I caveated mine on the day of earnings with "it's a crazy crazy call". It was obvious that one was risky af. I didn't have to make that post. I did it for fun. But Flywire, you've been pumping this thing all the way down. Stoney, these type of stocks are all in, or going to be... in the toilet. Did you see RBLX?! $23 Earnings beats mean zilch when a company makes no money Stoney. Reference my multiple "lemonaide stand" posts. There's quicky trades in an insane market, and there's stupid trades when reality sets in. Which one is Flywire at $19 and change? Think percentages Stoney... think about the children! Edit: The VZ tech bottom held. The bear dies slow however. Ya never know.